International Journal of Clinical Pharmacy

, Volume 40, Issue 6, pp 1458–1461 | Cite as

Effectiveness of antibiotic therapy in pediatric patients with cat scratch disease

  • Loujain A. Shorbatli
  • Katalin I. Koranyi
  • Milap C. NahataEmail author
Short Research Report


Background Appropriate antibiotic treatment of cat scratch disease (CSD) in pediatrics is not well established. Objective The purpose of this study was to evaluate the response rates of antibiotic therapy in pediatrics with CSD. Methods The electronic medical records of a cohort of pediatric patients with confirmed diagnosis of CSD (2006–2016) were reviewed, retrospectively. Data collection included patient demographics, clinical and laboratory results, antibiotic treatment and follow-up evaluations. Results One hundred and seventy-five patients (aged 7.4 ± 4.4 years) had confirmed CSD. Azithromycin and trimethoprim/sulfamethoxazole (TMP/SMX) were the largest groups with documented effectiveness at follow-up visits. Resolution and improvement of CSD was observed in 51.4% and 61.5% of patients with azithromycin and TMP/SMX, respectively among those with follow-up assessment. The effectiveness of azithromycin and TMP/SMX was comparable (p = 0.56). Conclusion Azithromycin and TMP/SMX were most frequently prescribed antibiotics. Azithromycin appeared to be an appropriate option for the treatment of CSD. TMP/SMX may be considered as an alternative antibiotic when azithromycin cannot be used.


Antibiotic therapy Azithromycin Cat scratch disease Pediatrics Trimethoprim/sulfamethoxazole 



We appreciate the assistance of Dr. Junan Li at the College of Pharmacy, The Ohio State University for the statistical analysis of the data.


No external funding was obtained for this study.

Conflicts of interest

The authors had no conflicts of interest.


  1. 1.
    Bass JW, Vincent JM, Person DA. The expanding spectrum of bartonella infections: II cat-scratch disease. Pediatr Infect Dis J. 1997;16:163.CrossRefGoogle Scholar
  2. 2.
    Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases Society of America. Clin Infect Dis. 2014;59:e10–52.CrossRefGoogle Scholar
  3. 3.
    Bass JW, Freitas BC, Freitas AD, Sisler CL, Chan DS, Vincent JM, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J. 1998;17:447–52.CrossRefGoogle Scholar
  4. 4.
    Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J. 1992;11:474–8.CrossRefGoogle Scholar
  5. 5.
    Holley HP. Successful treatment of cat-scratch disease with ciprofloxacin. JAMA. 1991;265:1563–5.CrossRefGoogle Scholar
  6. 6.
    Chia JK, Nakata MM, Lami JL, Park SS, Ding JC. Azithromycin for the treatment of cat-scratch disease. Clin Infect Dis. 1998;26:193–4.CrossRefGoogle Scholar
  7. 7.
    Dörbecker C, Sander A, Oberle K, Schülin-Casonato T. In vitro susceptibility of Bartonella species to 17 antimicrobial compounds: comparison of etest and agar dilution. J Antimicrob Chemother. 2006;58:784–8.CrossRefGoogle Scholar
  8. 8.
    Carithers HA. Cat-scratch disease. An overview based on a study of 1200 patients. Am J Dis Child. 1985;139:1124–33.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Loujain A. Shorbatli
    • 1
  • Katalin I. Koranyi
    • 2
  • Milap C. Nahata
    • 1
    • 2
    Email author
  1. 1.College of PharmacyThe Ohio State UniversityColumbusUSA
  2. 2.College of MedicineNationwide Children’s HospitalColumbusUSA

Personalised recommendations